Recruiting
Phase 1

CLN-619 & Pembrolizumab

Sponsor:

Cullinan Therapeutics Inc.

Code:

NCT05117476

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CLN-619

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information